JOINT FILING AGREEMENT
EXHIBIT
1
This Joint Filing
Agreement dated February 16, 2021 is by and between Camber Capital
Management LP, a Delaware limited partnership, and Xxxxxxx XxXxxx,
an individual (the foregoing are collectively referred to herein as
the "Filers"). Each of the Filers may be required to file with the
United States Securities and Exchange Commission a statement on
Schedule 13G with respect to common stock, par value $0.0001 per
share of Atara Biotherapeutics, Inc. beneficially owned by them
from time to time. Pursuant to and in accordance with Rule
13(d)(1)(k) promulgated under the Securities Exchange Act of 1934,
as amended, the Filers hereby agree to file a single statement on
Schedule 13D and/or 13G (and any amendments thereto) on behalf of
each of such parties, and hereby further agree to file this Joint
Filing Agreement as an exhibit to such statement, as required by
such rule. This Joint Filing Agreement may be terminated by any of
the Filers upon one week's prior written notice or such lesser
period of notice as the Filers may mutually agree.
Executed and
delivered as of the date first above written.
By: /s/ Xxxx
Xxxxxx
Xxxx
Xxxxxx
Chief Financial
Officer
XXXXXXX XXXXXX
By: /s/ Xxxxxxx
XxXxxx
